Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma, Ovarian Cancer
Interventions: p53: 264-272 peptide, CT-011; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Thymoma, Stomach Neoplasms, Pancreatic Neoplasms, Mesothelioma, Biliary Tract Neoplasms, Mesothelin Expressing Neoplasms
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Tamoxifen, Anastrozole, Fulvestrant; Drug
Lead sponsor: Priscilla McAuliffe; Other
Eligibility: Female only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more

Conditions: Pancreatic Neoplasms
Interventions: Avastin (Bevacizumab), Gemcitabine, Radiation Therapy; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: NAFLD, Diabetes, Obesity
Interventions: GLP-1 receptor agonist; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 874 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 48
States / cities: Chandler, Arizona • Gilbert, Arizona • Greenbrae, California + 29 more

Conditions: Type 2 Diabetes
Interventions: Cocoa polyphenols; Dietary Supplement
Lead sponsor: Arpita Basu; Other
Eligibility: 21 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Stillwater, Oklahoma

Conditions: Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma
Interventions: talabostat mesylate tablets, gemcitabine; Drug
Lead sponsor: Point Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 28
States / cities: Florence, Alabama • Muscle Shoals, Alabama • Hartford, Connecticut + 20 more

Conditions: Obesity, Prediabetes
Interventions: Mirabegron; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine, Laboratory Biomarker Analysis, Poly ICLC; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 17
States / cities: Tucson, Arizona • Duarte, California • Sacramento, California + 11 more

Conditions: Diabetes Mellitus Type 2
Interventions: placebo, taspoglutide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Santa Ana, California + 7 more

Conditions: Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
Interventions: Amlexanox, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin 500 mg tablet; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Charlottesville, Virginia • Richmond, Virginia

Conditions: Type 2 Diabetes
Interventions: Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs; Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: New York, New York • Charlottesville, Virginia

Conditions: Endocrine and Metabolic Responses to Exercise and Diets
Interventions: Exercise and diets; Other
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer
Interventions: Docetaxel, PTK787; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cushing Disease
Interventions: Fimepinostat; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes
Interventions: standard of care insole, 3D Printed Insole - pressure based, 3D Printed Insole - FEA; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Tachycardia, Diabetes Mellitus, Cardiovascular Disease
Interventions: Subcutaneous Implantable Cardioverter Defibrillator; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 36
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 31 more

Conditions: Adrenal Tumors, Adrenal Malignancies, Abnormal Hormonal Secretions, Electrolytes Abnormalities
Interventions: Imaging, Adrenal acans, (NP-59); Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1977 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: PET Scan; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Growth Hormone Deficiency
Interventions: LUM-201; Drug
Lead sponsor: Lumos Pharma; Industry
Eligibility: 5 Years to 14 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Iowa City, Iowa • Worcester, Massachusetts • Kansas City, Missouri + 3 more

Conditions: Solid Tumors
Interventions: Avelumab; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 26
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Sacramento, California + 20 more

Conditions: Pancreatic Neoplasms
Interventions: nab-Paclitaxel, Gemcitabine, Chemoradiation, Capecitabine, Surgery; Drug · Procedure
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 23
States / cities: Scottsdale, Arizona • Sacramento, California • San Diego, California + 20 more

Search by objective public record fields.

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

Endocrine Response in Women With Invasive Lobular Breast Cancer

Preop Chemoradiation Resectable Pancreas

GLP-1 RA on Liver OMICS in MASLD

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

ADRB3 Signaling Pathway in Human Adipose Tissue

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients

Pharmacogenetics of Metformin Action in PCOS

The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

Exercise Effects on Insulin, Gut Peptides, and Appetite

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

Patient Specific 3D Printed Diabetic Insoles to Reduce Plantar Pressure

Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator

Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)

Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

Avelumab Program Rollover Study

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)